The incidence of malaria in Britain as reported to the Malaria Reference Laboratory during the past decade has increased by 51%, from 1529 to 2309 cases, and infection with Plasmodium falciparum has increased from one fifth to one third of ali cases. The case fatality rate for P falciparum infections declined from 2-7% to 0*5%. Of the 67 persons who died, 54 were of British origin, nine ofAsian descent, and four African. Sixteen had taken chemoprophylaxis; of these, nine had taken pyrimethamine alone.
Introduction
The last review ofmalaria in Britain was published by Bruce-Chwatt and his colleagues in 1974.' Since then the epidemiology and prevention of malaria have become increasingly complex world wide and nationally. Attempts to contain malaria have been thwarted by social and financial constraints so that control measures have replaced attempts to eradicate the disease.2 Transmission of malaria has increased because of changes in agricultural practices and movement of migrant populations, vector resistance to commonly used insecticides, and the resistance of parasites to chemotherapeutic drugs.
Strains of Plasmodium falciparum have become resistant to chloroquine and other antimalarial drugs and are spreading through Africa and Asia. More travellers are visiting areas of resistance where the transmission of malaria is high, and the risk of adverse drug reactions increases when alternative drugs with greater prophylactic efficacy are used. Thus groups of travellers who have a high risk of becoming infected with malaria need to be identified and protected. This requires an understanding of the epidemiology of imported malaria and knowledge of the efficacy and safety of prophylactic drugs.
Malaria, 1977-86 INCIDENCE Over the past decade 18 374 cases of malaria were reported to the Malaria Reference Laboratory, ofwhich 5015 (27%) were infections with P falciparum (table I). The numbers have progressively increased after a fall in the early 1980s and in 1985 and 1986 exceeded 2000 a year. The previous peak in the number of cases in the late 1970s was associated with new immigrants entering Britain, whereas now the data suggest that the groups who are importing malaria are already resident in Britain and travel for short visits to malarious areas.
An accompanying increase in the number of cases of infection Cases of malaria from south Asia account for over half of all cases imported into Britain each year. As in previous years these are predominantly P vivax infections. Eighty four per cent of all cases ofP vivax infection are imported from south Asia, mainly in settled immigrants who visit friends and relatives. There was a notable increase in cases from Pakistan but a steady decline in cases from India until 1984, after which both continued to rise. There has, however, been a reclassification of settled immigrants who had been misclassified as "Indian" by reporting agents. Incidence rates were calculated per 100 000 travellers arriving in Britain from these countries (table III) . Between 1979 and 1984 the incidence of P vivax from India declined, but rates for P falciparum increased 20-fold. During the same period the rates of both P falciparum and P vivax infections increased 10-fold in travellers returning from Pakistan. Rates of P falciparum infections are still low compared with those from countries in Africa, but this trend is notable because it follows the epidemiological pattern of malaria in south Asia, reflecting a relative increase of P falciparum.3 Of concern is the spread of resistance to chloroquine through south Asia.
POPULATION GROUPS AND REASON FOR TRAVEL
The pattern of imported malaria in different population groups has changed over the past 10 years (table IV) . In 1977 cases were distributed equally between foreign and British residents. During the early 1980s there was, proportionately, a higher incidence in British residents.
British residents-The incidence of malaria in British residents has doubled since 1977. The greatest rise has been in settled immigrants who visited friends and relatives, with an increase from 55% to 66% of all malaria cases in British residents. These are predominantly P vivax in residents of south Asian origin. The number of cases of malaria in British residents travelling for other reasons has remained under 500 each year-about a quarter of all cases, most of them in tourists and business travellers. The incidence of malaria in tourists varies each year but is less than 200 cases a year. These are mainly holidaymakers visiting Kenya. Business and professional travellers acquire infections from Nigeria, Kenya, India, and Papua New Guinea. The incidence in other groups such as British residents who live overseas, schoolchildren visiting parents abroad, civilian air and sea crew, and military personnel have increased threefold to about 100 cases a year.
Autochthonous cases-Twenty four cases of malaria acquired in Britain ("autochthonous cases") were classified as congenital, transfusion, and airport malaria. During the past decade congenital malaria was reported in 14 babies. Of these, two had infections with P falciparum and both were of African origin. Eight of the 12 patients with P vivax infections were of Asian origin. Ten cases of malaria were recorded in patients who had not travelled to malarious areas; six of these were associated with hospital treatment, in four of which the patients were infected with P falciparum, having received blood products. In 1983 two cases of P falciparum were Of those returning from west Africa, nine travelled to Nigeria, mainly on business. Case fatality was highest in cases from the Gambia (5 8%) and Malawi (4 8%) and lowest from Nigeria (0 5%) and Ghana (0 6%). These rates clearly have some relation to the immune state of the infected travellers. Three deaths were reported during 1985-6 in people returning from the Gambia, a country not previously associated with fatal malaria in Britain. This is alarming because the Gambia is being promoted extensively as a tourist resort.
The documentation of the use of prophylactics has been scanty and, until recently, follow up of data was incomplete. Comprehensive information on compliance with prophylaxis in travellers who have died has not always been available. Sixteen of the 67 patients who died were reported to have taken a chemoprophylactic drug, nine of whom took pyrimethamine alone (Daraprim). This has not been recommended by the Ross Institute as a prophylactic for several years. 7 It is of concern that of the nine deaths in 1985 and 1986 three were in travellers who had been prescribed pyrimethamine. To determine the efficacy of different prophylactic regimens and the changing patterns of resistance we need accurate reporting of the chemoprophylactic state of patients. Malaria reports need to include the name, dose, and duration of use of the antimalarial and the patients' compliance with the regimen.
USE OF PROPHYLAXIS IN TRAVELLERS WITH MALARIA
Tourists who visit Kenya are particularly exposed to infection and death from malaria. Of those who died and are known to have taken a chemoprophylactic, over half had taken pyrimethamine alone. The use of this drug in non-immunes has been considered unsatisfactory for some years. Though a knowledge of drug use in the general travelling population is required to establish the true association of risk, these data suggest that pyrimethamine taken alone is inadequate. Recent deaths from the Gambia are a cause for concern. Tour operators play an important part in making travellers aware of malaria and protecting their clients.
Calculating attack rates helps to define the travellers at highest risk of contracting malaria. More detailed studies are required to define the groups at risk and the efficacy of the prophylactic drugs in use. Immigrants to Britain who visit friends and relatives are consistently at greatest risk, and though transmission in Africa is greater than that in Asia, rates for visitors to both countries were similar. This may reflect the long duration of visits made by immigrants to their relatives. These groups should be offered adequate protection. Asian immigrants who visit relations in a highly malarious area are often unaware of the risk because they emigrated from the area at the height of the eradication programmes in south Asia. Many also believe that they retain lifetime immunity.
Malaria in young children seems to be disproportionately high. Susceptibility may result from absence of prophylaxis, poor compliance, or the use of drugs of low efficacy.
Malaria continues to impose a threat to international travellers, and doctors need to be vigilant in diagnosing and treating the disease. Reporting cases of malaria to the Malaria Reference Laboratory and suspected adverse drug reactions to the Committee on Safety of Medicines is essential to balance the risks and benefits of prophylactic drugs.9
